Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mupirocin + sucralfate
- Development stage
- Unknown
- Lead developer
- Strassenburg Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
mupirocin + sucralfate (marketed under the brand name Sucral MU) is a topical combination ointment developed by Strassenburg Pharmaceuticals for wound healing and the treatment of bacterial skin infections. It contains sucralfate (7% w/w), a cytoprotective agent, and mupirocin (2% w/w), a topical antibiotic. Sucralfate acts locally by polymerizing in acidic or damaged tissue environments to form a protective, adhesive barrier over wounds and ulcers, shielding them from further irritation and promoting tissue regeneration. Mupirocin is a protein synthesis inhibitor that specifically binds to bacterial isoleucine--tRNA ligase (isoleucyl-tRNA synthetase), preventing the incorporation of isoleucine into bacterial proteins and thereby halting bacterial growth. This dual-action formulation is indicated for the treatment of burns, diabetic foot ulcers, bedsores, pyoderma, impetigo, and post-surgical wound care (such as post-caesarean-section and post-gynaecological-surgery care).
- Brand names
- GolcinHEALbactMotoseal-SFMupigardSucrahelp MUSucral MU
- Other names
- mupirocin/sucralfatesucralate MUsucralfate + mupirocinsucralfate/mupirocin
02
Targets
IleRS (Isoleucyl-tRNA synthetase)PEP (Pepsin)
Beyond the preview
Go deeper on mupirocin + sucralfate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mupirocin + sucralfate.